-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 BraffeeykHfbBKgOgqRL3levUZ+C/yuqgUdjgqtmsIgPuPdecBvBTc5IBLZESv5P
 fk1L4qlOyHXUsQD7DnpZQQ==

<SEC-DOCUMENT>0000950144-08-005653.txt : 20080723
<SEC-HEADER>0000950144-08-005653.hdr.sgml : 20080723
<ACCEPTANCE-DATETIME>20080723142658
ACCESSION NUMBER:		0000950144-08-005653
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20080722
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20080723
DATE AS OF CHANGE:		20080723

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Geovax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			IL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		08965527

	BUSINESS ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306
		BUSINESS PHONE:		404 727-0971

	MAIL ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>g14343e8vk.htm
<DESCRIPTION>GEOVAX LABS, INC.
<TEXT>
<HTML>
<HEAD>
<TITLE>GEOVAX LABS, INC.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>






<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>


<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>
Date of report (Date of earliest event reported): July&nbsp;22, 2008</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>


<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>GEOVAX LABS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">
<B>(Exact name of registrant as specified in Charter)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware<BR>
(State or other jurisdiction of <BR>
incorporation or organization)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-52091<BR>
(Commission File No.)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>87-0455038<BR>
(IRS Employee Identification No.)</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
<B>1256 Briarcliff Road N.E.<BR>

Emtech Bio Suite&nbsp;500<BR>

Atlanta, Georgia 30306<BR>

(Address of Principal Executive Offices)</B></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
<B>(404)&nbsp;727-0971<BR>

(Issuer Telephone number)</B></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the Registrant under any of the following provisions (see General
Instruction A.2 below).</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR240.14a-12)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4&#169; under the Exchange Act (17 CFR 240.13(e)-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">








<!--TOC-->
<!--/TOC-->





<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#147;registrant&#148;) from time
to time with the Securities and Exchange Commission (collectively the &#147;Filings&#148;) contain forward
looking statements and information that are based upon beliefs of, and information currently
available to, the registrant&#146;s management as well as estimates and assumptions made by the
registrant&#146;s management. When used in the Filings the words &#147;anticipate&#148;, &#147;believe&#148;, &#147;estimate&#148;,
&#147;expect&#148;, &#147;future&#148;, &#147;intend&#148;, &#147;plan&#148; or the negative if these terms and similar expressions as they
relate to the registrant or the registrant&#146;s management identify forward looking statements. Such
statements reflect the current view of the registrant with respect to future events and are subject
to risks, uncertainties, assumptions and other factors relating to the registrant&#146;s industry,
operations and results of operations and any businesses that may be acquired by the registrant.
Should one or more of these risks or uncertainties materialize, or should the underlying
assumptions prove incorrect, actual results may differ significantly from those anticipated,
believed, estimated, expected, intended or planned.
</DIV>
<!-- link1 "Item&nbsp;8.01 Other Events" -->

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;8.01</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Other Events</B></TD>
</TR>
</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On July&nbsp;22, 2008 we issued a press release announcing the signing of a letter of intent for
joint collaboration and commercial license of vaccine manufacturing technology from Vivalis S.A..
A copy of the press release is attached to this Current Report.</DIV>

<!-- link1 "Item&nbsp;9.01 Financial Statements and Exhibits" -->

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;9.01</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Financial Statements and Exhibits</B></TD>
</TR>
</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibit&nbsp;99.1 Press Release</DIV>

<!-- link1 "SIGNATURES" -->

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>SIGNATURES</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dated: July&nbsp;23, 2008
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">GEOVAX LABS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Mark W. Reynolds
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Mark W. Reynolds&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="right" style="font-size: 10pt"><!-- Folio -->2 of 2<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>g14343exv99w1.htm
<DESCRIPTION>EX-99.1 PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-99.1 PRESS RELEASE</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><IMG src="g14343g1434300.gif" alt="(GEOVAX LOGO)">
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><IMG src="g14343g1434301.gif" alt="(VIVALIS LOGO)"></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">GEOVAX
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">VIVALIS</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Media Contact: Melanie Nimrodi
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Media Contact: Steve Grobet/Emmanuel Huynh</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#043; 1 312.546.3508
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#043;33 (0)&nbsp;1 44 71 94 91</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><U>mnimrodi@frbir.com</U>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>vivalis@newcap.fr</U></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company Contact:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Company Contact:</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Robert McNally / Jennifer Nelms
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Franck Grimaud</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">1 404.727.0971
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>investors@vivalis.com</U></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">FOR IMMEDIATE RELEASE
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GeoVax Partners with VIVALIS for Use of its Revolutionary EBx</B><B><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Technology to<BR>
Manufacture its MVA HIV/AIDS Vaccine</B><BR>
<I>Partnership creates worldwide strategic collaboration between Vivalis and GeoVax</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ATLANTA (GA &#151; USA) &#038; NANTES (France) July&nbsp;22, 2008  &#151;  GeoVax Labs, Inc. (OTC BB: GOVX), an
Atlanta based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1
(Human Immunodeficiency Virus) and other infectious agents, together with VIVALIS (NYSE Euronext
:VLS), a French biopharmaceutical company that provides innovative cell-based solutions to the
pharmaceutical industry for the manufacture of vaccines and proteins, announced today the signing
of a letter of intent (LOI)&nbsp;for joint collaboration and commercial license on the use of Vivalis&#146;
EBx<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> technology, to manufacture the MVA component of the GeoVax HIV-1 vaccine.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This agreement between GeoVax and Vivalis creates a worldwide strategic partnership between Vivalis
and GeoVax, designed to combine Vivalis&#146; cutting-edge vaccine manufacturing technology with
GeoVax&#146;s promising HIV vaccine.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The breakthrough manufacturing technology developed by Vivalis, and now to be further developed
through collaboration with GeoVax, will create a new standard for manufacture of the MVA component
of the GeoVax HIV/AIDS vaccine, making present manufacturing technologies which have limited
production capabilities, less competitive. Vivalis&#146; EBx<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> manufacturing platform, with
its increased effectiveness, superior quality and reliability, will speed time to market MVA
vaccine product availability in ample quantities to meet sizeable demand and expectedly at a lesser
cost.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;Partnering with Vivalis and its cutting-edge technology is extremely significant, and a giant step
forward for efficient manufacturing of our &#145;MVA&#146; HIV/AIDS vaccine component,&#148; stated Robert
McNally, President and CEO, GeoVax.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;VIVALIS is pleased to enter in this collaboration with GeoVax, one of the most advanced companies
worldwide in the field of HIV vaccine development. This agreement aims at developing a VIVALIS
proprietary upstream-downstream process for the production of MVA vaccines and EBx<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
technology licensing. GeoVax becomes a strategic partner and joins an elite worldwide consortium in
the field of development, purification and production of MVA based vaccines,&#148; said Franck Grimaud,
Vivalis CEO<I>.</I></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The EB66<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> cell line is becoming a new standard for the production of vaccines, leading
to Vivalis having signed more than 20 licenses prior to December&nbsp;2007 and four licenses in 2008:
two research and two commercial.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Vivalis&#146; vaccine manufacturing technology is based on a duck embryonic stem cell substrate
platform. The EB66<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> cell line provides continuous growth from a fully characterized
frozen cell bank, without necessitating fertilized embryo extraction and processing, as with
present chicken cell based technologies. Furthermore, the EB66<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> cell line can be grown
in suspension (without the cells attached to the surface of the growth vessel) and</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>GeoVax Labs, Inc.<BR>
Add 2</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">can be scaled up
for growth in giant bioreactors (a cutting edge industrial method) for large scale production of
the MVA viral vaccine.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Last month, Vivalis announced the filing of the BMF (Biologics Master File) for the
EB66<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> cell line with the US FDA (Food and Drug Administration). Extensive testing
reveals the unique and innovative nature of Vivalis EBx<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> technology for the production
of vaccines and proteins. Today, the EB66<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> cell line is the only available
cell line in the market to be immortal and diploid.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;When we learned about the work of Vivalis with EBx<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> cell lines that might be able to be
used to grow MVA, we contacted Vivalis and arranged with them to jointly conduct pilot studies on
the growth of our MVA vaccine,&#148; said Harriet Robinson, Senior Vice President of Research and
Development, GeoVax. &#147;Our early production results have been very promising and have led to this
LOI for more formal development of the Vivalis EB66<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> cell line for the production of our
MVA vaccine.&#148;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The GeoVax vaccine is a DNA/MVA vaccine that uses recombinant DNA to prime the immune response and
then a recombinant MVA virus to boost the immune response. MVA stands for Modified Vaccinia Ankara,
a smallpox viral vaccine that was attenuated (made more safe) by replicating the vaccine virus over
500 times in chicken cells. This long series of replications resulted in a derivative of the
smallpox vaccine virus which could grow in chicken cells but that had limited ability to grow in
human cells. The poor ability to grow on human cells has made MVA a very safe vaccine vector for
humans. However, it also limited the ability to manufacture MVA in the industrial cell lines that
have been approved for vaccine production. Rather, MVA had to be grown in chicken cells which rely
on harvesting cells from thousands of chicken embryos and using these cells which are grown in
multiple small vessels for vaccine manufacture. This process can be done for clinical and
commercial production, but is cumbersome, fraught by the introduction of contaminants and
expensive. The Vivalis EBx<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> manufacturing technology eliminates such difficulties and
enables rapid large scale production in bioreactors for GeoVax&#146;s future commercial needs.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Financial terms of the agreement have not been disclosed. However, each side shall fund its roles
respectively, depending on developmental or process responsibilities assumed by each party. An
upfront amount payable to Vivalis will be provided as consideration for the signing of the LOI.
GeoVax&#146;s development and license payments shall be made based on milestone achievements. Royalties
on GeoVax net sales are also included. In addition, applications have been filed for EU and local
government financial participation. GeoVax is also seeking FDA guidance on the Vivalis
EBx<SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP> manufacturing program recently submitted to the USA FDA allowing usage of
<I>EB66</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP> produced MVA vaccine for GeoVax&#146;s ongoing human trials.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Earlier this month, GeoVax also announced an operational update on the company&#146;s progress towards
entering Phase 2 preventative human clinical trial testing and plans to proceed into therapeutic
human trials with its AIDS vaccine. The Company&#146;s Phase 2 trial, to be conducted by the U.S.
National Institutes of Health (NIH)&nbsp;and supported HIV Vaccine Trials Network (HVTN), will involve
225 healthy volunteers from the United States and South America, and will further evaluate the
safety and immunogenicity of the GeoVax preventative vaccine (vaccine administered prior to
infection with the AIDS virus). The GeoVax DNA/MVA vaccine uses a different viral vector (MVA)&nbsp;than
the Merck vaccine and the NIH Vaccine Research Center vaccines, which use adenovirus5 (Ad5)
vectors. The Merck vaccine was withdrawn from trials in September&nbsp;2007 because of failure to
protect. The NIH has just announced that their vaccine will not be progressing in large scale
trials because of the Merck results. Thus two major competitors for GeoVax are no longer
progressing in trials.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><B>About GeoVax Labs, Inc. </B></U></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and
commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other
infectious agents. GeoVax&#146;s HIV/AIDS vaccine technology is the subject of 20 issued or filed patent
applications. GeoVax HIV/AIDS vaccines are designed for use in uninfected people to prevent
Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person
ever become infected. GeoVax HIV/AIDS</DIV>



<P align="right" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>GeoVax Labs, Inc.<BR>
Add 3</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">vaccines also may be effective as therapeutics (treatment of
people already infected with AIDS virus). Studies evaluating these vaccines in HIV/AIDS infected
individuals are in the planning stage.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax&#146;s core HIV/AIDS vaccine technologies were developed through a collaboration of colleagues at
Emory University&#146;s Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease
Control and Prevention (CDC)&nbsp;and the GeoVax team.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax HIV/AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine
Trials Network (HVTN)&nbsp;based in Seattle, Washington. The HVTN, funded through a cooperative
agreement with the National Institutes of Health &#091;NIH), is the largest worldwide clinical trials
program dedicated to the development and testing of HIV/AIDS vaccines. Preclinical work enabling
evaluation of GeoVax DNA and MVA vaccines was funded and supported by <B>NIAID</B>, which provided
additional support to GeoVax AIDS vaccine development program with a $15&nbsp;million IPCAVD grant
awarded in late 2007. www.geovax.com</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><B>About VIVALIS</B></U></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based
solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops
drugs for the prevention and treatment of viral diseases. VIVALIS&#146;s expertise and intellectual
property are exploited in three main areas:</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1. The development and manufacturing of vaccines. VIVALIS offers research and commercial licenses
for its EB66<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> cell line, derived from duck embryonic stem cells, to pharmaceutical and
biotechnology companies for the production of viral vaccines. Vivalis receives up front,
milestones, and royalties on its licensees net sales.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2. The development of production systems for recombinant proteins and monoclonal antibodies.
VIVALIS licenses its EB66<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> cell line for the production of recombinant proteins to
biotechnology and pharmaceutical companies. Vivalis receives up front, milestones, and royalties on
its licensees net sales.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">3. The construction of a portfolio of proprietary products in the area of vaccines and anti-viral
molecules (hepatitis C).</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud group (1,450 employees), the
second largest group worldwide in animal genetic selection. VIVALIS has established numerous
partnerships with world leaders in this sector. VIVALIS is a member of the French ATLANTIC
BIOTHERAPIES bio-cluster.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Safe Harbor Statement: All statements in this news release, not statements of historical fact, are
forward-looking statements. These statements are based on expectations and assumptions on the date
of this press release and are subject to numerous risks and uncertainties which could cause actual
results to differ materially from those described in the forward-looking statements. Risks and
uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these
vaccines with the desired characteristics in a timely manner, GeoVax&#146;s vaccines will be safe for
human use, GeoVax&#146;s vaccines will effectively prevent AIDS in humans, vaccines will receive
regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to
complete vaccine development, there is development of competitive products that may be more
effective or easier to use than GeoVax&#146;s products, and other factors over which GeoVax has no
control. GeoVax assumes no obligation to update these forward-looking statements, and does not
intend to do so. Certain matters discussed in this news release are forward-looking statements
involving certain risks and uncertainties including, without limitation, risks detailed in the
Company&#146;s Securities and Exchange Commission filings and reports.</I></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">###</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g14343g1434300.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g14343g1434300.gif
M1TE&.#EA%0$N`.8``-3;Y*BWR"I&<X69L/O]ZLC8XKC)V,?3W#A4>_[^^",Z
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M^,/0WTUN@O#X^B)`7_[]_OW^^^GJ\'J2G2].;YJPSX^]T?___R'Y!```````
M+``````5`2X```?_@'^"@X2%AH>(B8J+C(V&&AL(4`->CI:7F)F:FYR=GI^@
MH8LD/$P/7:*IJJNLK:ZA)ENR6S=>MK>VLULFEU@]"CT%K\/$Q<;'@K$Q;1<5
M70P`1$YF'1T!;V]L8FQL&20#X.`E`QG:;"/83QT&!P!"2!H5(!=>NVL"/!9X
MR/S]_O^#3,0`44%#`0,=WF2P,*7&&`$J4/!!(>`$$SX\7K1`<8+%BQ-R0K*0
M\R(-#SEI4*($J4)`&@%W5""H8<0"C`\D%"B8T05$#EX`@PH=BFE+FRY$SI"Q
ML*0'114J/K[XR,3%'11R%$"!,I'%F#$H6H2HL<2($3=HT3;0H6.#FX8U_Q`@
M>#&&Q8D[:528O&.A0-0054[TV&&!3!4B7=IX`4JTL>-^&,X\V`"!1<LT+%R<
M4`&2A0`FGD^<H,EF10HZ!X0P^%"AS:`MB/8A\E*0@0@A:M0$*'%@@PH%`2B<
M2"F'A64F$'8\J&+GL?/GJ;:(F&&EQ(X%?#ZFW/Q"A0L6/%`LH'#%PH@9*0Z(
M.")%=J@(A)3P,@%"1H$>=^Z(&&'ARA($<H"F0`L=U4!!&&^D`$`.T#7HH"(7
M%#`##&XLH`!GW7&&CP+(+7%%"2/\8(`(("CQAPGN96)B(2DRDH%G(0P"!`,'
MH.?`%3LXY0(3"$`5PA49K'!`)0\6Z=P1:TBP`_\$$)W$`V9IY,?'`@]8H:`&
M?ZRHB);Q,18;4.YYX,$?'DQ0B!(>^+``$PI(8`B*@E0@!!$K6!>"72R@X-4.
M(QQPA)&`_I,#'0T@@$)>+KS`1QIIL,D"#4.LH<$%7O[1(B%`"'(I(4G`=R:7
M>*QH@@EQ>!K0/AU`A`(JCLQ1`0,I+!$"10^A@,`&!UP0Z*[#M-$!!-W)<8(`
M+.27A@("3/&$'C=L@L>F658:@:F6)##FB:-:H(`<%&2J"0@,4"&:"CPH(!X5
M4D3@P;0)$$!`'!-,0("9TZK+KKP)U/M'O>M&D`"^^M;;[@3YVCOM'_)..T$$
M\9;*L+_U^CMOP?W"E_#_P_VNNW`$\^X[;<8/<TQOQ/`N'$>I'?-[+P$%PZ<O
M(@PXX)!'/+"0EV=C]$`&!WK$P*4)>3#@1'46A-&`!0TD_8`#%6`[R,'4>I#`
MJ(.8&9`365A0PA<%"T*M(!CTD)(!619B`I>$4)T,"$T$P%0++WA%@P-?Y.&!
M"6+F+2:9=_.-]]U_^^VWF*/N3?C?@0=.^.)Y(^XXXR<:?C?A?$<^^9B4[XVX
MY(4W#GGFEW<N>"%>?&%%#V-@&"`/3_8@Q@Q--/LF!C\L\!`/'0F@.T?$OO''
M%B9&O>^^)B:0P"#7#J)!`[AG<,/>9)XXP;4_"*!``[I6JC9C\(5ZYA]M,!#`
M_P-0#"<`#1(`$`.O[&>B009\Z.Y2&B=,Q<("#H"@B`E-/"`:$TQ`P59",$!)
MG*`$)Q*$MQ:AA>&MRUJ"*``$[K``)#P-;^K:5QDVP(0Q'``19R,3?*Z%!P\\
M2Q%?R$`='I*&,3@``^V+X2),0`2Q1:0%R*(("G0``/TI`@M4P$X:$-``#GS@
M`A?(00XN@`80M($(5HC6!.)@*1ML#'D$@)X@CB<(EL5!#589@=/6%9`U0,4"
M##J$V@310`\H@8M`21[IZ&`A)JB@!R*HE`SW6($0$`L\*KB#<52P@:8Q@@$]
MJAG9"G&\%>4`2\D0!*C@92(R*D(#".#+%K0XB`L$H/]<`4B$?/#&Q3^4TE(G
M@L\:"?$!U*5D`QA`VQ[91T,+R*%F3!!`"_3"!Q)PH1!E,I[#(I"#!\A!!2&8
M`18,<<I!:(E@A,"#'@G&Q3(-P@MND$,(9+!%:RTL`4Z8@AQ:`(9$2!-O6E!"
M`[N9K^DE0X]_2,('4A"")]'@@[.481,64#^+X.X%`J#`$W1U"&$JK`#XX$,H
MXV/*?9CI>"@*WB#R);7DY<%XP2P8O/(EB"?4CSFF]&8$I%`"O5A`=H<`7D!X
M044NJDN:)$3$%IS0@W+M@`'YC&%)^2`:/4$%`3AH1*9R<(686,"'FC+1&N>3
MAX#`QP=@^$"SK.6II6+@`TC_`,&U9+"$B'#`$&M8`%3H,(@NK*$``*@`#3EP
M`"D0H`!L5<,'M.>#`SC!"4*093+6@`!&.2"G[8.`"N10$<O(P07XG.A$3<4+
M1)[`@V9C3!S@^0<I6*`&=FD!$W8P@Y^830TUX!T*-F"`")C``2=0@!L,886[
M]&`.92`41!["@@9TX"$]*(,(W("",2"`FX0X@&7&0`4<4/9$*R#)!@#+/BCP
MP`4M*.R.YI`E+6F,G8(@`H&&\">&(FP0<=!"'-!0,`(\@`>?<8$"[-(#LEW4
M80>``$6J@I(%L.$&3AC#':`@@WY9ZPJB@<$?#%`#JR@@.W$;`!2@BPH-/,`J
M;_@7_WQL((9BD6"!;Q($#L;P@A@Q=U<M",U)A-6`=S(B`AWX#0>\E(,#5$$"
M58BQ!&;\`QC^00\4N!D-KK"!!<2-#RN`S1]`X`8$''@!;EF`S>0P@".XP20S
M(`0.>L0'(00@=6GHP0;6$@)SL:`%+>"F";X`@<TP[0\RV``^EF!C$.XC!S#@
M`PT^O"L*?`1/+%!`!C2U#P(T=1!:.)Z8\/`$J#BA$`<(P;B$!14](3`/%ACL
M`][``((0P0%0>`$"GG`B*V0$!5:H-`C`D($Q?.<)`1#D#@CZ!S&@EP9?"$%+
M'K"&"EP`!`5PPPN8\)$V'T`S?(#!%N!WD34L0J5;,``+$/](9T`](3OHM8P+
MKB"(/`#%!&C0@A8\%<P__$`!=_CJ(/`P@H[@\G_E6@(-=[F#0P2`6"W0P`?6
M)(`.D.[*/-C!&B#``Q4$X5]2J`,/0K""#%3$"FCC:MR8`$E!9$"04`A`=E"P
MYT5(,P(7",,"A-%L(WFA!"APP8X$`(4QP,?::)#C(<PP!@4\(8V">,,`H@&`
MF@.``PB84@4R\!M#%@($YV7!`5:`CRD<(@<S4``"G!!G!8A!$$$X5`;L4`,%
M7.$"23#$&<AU`N`.8@?])I8*&B!D15P<H7V`5L<?LX4F#*`BHOE(8A%!`$(`
M``4J@,,7"%&`H++LNV6H)PTTH`/_3?]<#WK00`FFH@8'L$[`APA"7@(@A#I8
M77]4L-D3-("".V0`PX/``13`W&9!<(`C]:N#O1U1AB)<H9QK!U0%2""`J2B`
M!PMH@I;L)35/&>\/%5A`OP-0]@5ZSY3UK,$7ZM+N01B`!@OHP0+*MY,!(.NO
MA-#"J#BO@+]*0"L&"/X+=O`!/;3@#BE(1/E0T/!!O*$4*OB!R@\A'PR,X`EE
MB/VN8O`&1=^A)%>@!G]0=UM$2H(`/0X`$S30!&KD'CTP&@R`60M`"`"6&1\!
M$@8P`.CE.]'$"Q^`=W]U!!AA`57`)F_@!1J`0RL`3W90/@*@!X6@!UU%(*35
M"$CP`TZP_TSZQRLYT`$+(`#?@0)B$`,<50A6(PA=4!EIX`;-H0@/N`!V0`;J
MA50/4`<68`$/\``4T`=_$`#'TGP#.`AET`&-8F]`4`3H!1$0\`%_8`<]H`),
M*$LI@`(\T`(^)PBRQ@.9YA4,F`@QP`$`0"0[:"2R]``<4BX/@%)><X1FL@6!
ML1DD4`BF4G?UU`,FH`8Z00&2]%=H`'H`D$DG$%15,P%.0"X]`'L%H``O<$L6
ML#XFL`=W(`!DA38ZH(KL1PA58!("H`8(P#HZ($IS4':#""A24PAJ,`7((@!+
M(`(7$`<7Y5*FT@8TP#H*8`%L:#5%^`<U50-_<`$T`!$SP`6TD?\(%E`54'@P
M?U!YF%$"^9<E$'`L"F``?U8`*'!@`;`^@W`&`H`"`=1F6\`'B3(`?_`B`C`&
M'$<(KC*,[,-%OQ<0&#`^];0`&2`"?X8\T'0#;X``3'`75$(&5#`",$`%$D`%
M""`8IA<"Q1$")2`!*[`"`?"2+\D`>-`$?35PYC$"#Y`ZRBB*#G<A$-!P7C``
M4)$&%)`!(T`&&Y`&<',"MP@^5\!3UB@("J9T!H`#0G``:/4!6:<!!V!C6[`&
M1.`:E@``;R"6F\`_'`"(QX4(&C``<W4)-%0`^G,#!2`"K-`&#@``H[*6OS19
M@F`UO(`'6U``5K`'"U`#&7``'V`XII+_;#3`&2C1'>42-U+1`X/P!"T7716A
M`IZA.V.7`TI`!`]@1\4!$C53`T%0"`6@7R50=@G0!190>XKR$N12!WPP3G]2
M!F_P93O0A-T8`-LR!FY0!#.@B&08`+P``!#@!NW'"!)``?BH"5L0``L0`B%`
M`\+8"`"P`'MW"2`0`A`@!'^`4&'`"D>``'+I-J"G*:="""KG`4D@`S-``N,!
M`T1@`WI4`0X`!PM@*'SPGWG"`O&#`MWY!Z))`Y(`!?N(`KW%!V/``<!S`]19
M<DP0`DOP!MU%"!5@`6,``(1@)A>@!B70`PA0D#^"!&%0HAT0!"4P*U!0H((`
M`B2P`T]P!(J8_UUR0`8Y<`.19@`R0`0`@`1CHEL`T`05L`4@4',:4`8?L`9M
M-P='```V5@9-0`0:4`D74*5?@%(@``5A@`%V0%9M(`)$T`2PT092"@`,\`65
M@`%?``)-"@05(`(R``!Z0"0X```?X*:,P0`!U1PC<`<K,*:+P05L&@--@`%J
M>F,])`@:H*2PP0#Q8*6"(`4%8*E\@`#R9F/R9BGN])<9-":K1`A!,`0+<`8`
MP$WJ<H1_$`14,`11D`5P$`4-$`5P``=#\`.%(`-DX`:X&@5#,`0-$*Q5P&I'
MX`?`Z@=(Q2(=$`8P9PA!4`1#4`0<5P$!`*NQBJN+=`E(P`)'U04(0/\#>B`!
M8P`!<-`T3:`#$%`#9J`!3U`#-0`##%`$3\``4U``,(``52`(7[`$)S`$'GH`
M"Y`&.L``0*$'8U`"#,(+'#`%*%`#6`(`4W`Z0P`'^F,%1K`&5%`%0-`!.A``
M$"`&>Z<!<``!4="L,2`;`%"-@O```I`":P`'&&`",2L#0=``9Q"O.1`&$#`#
MO``#7T$%%>`%)'`&OP(#E5``1<`!NE8#14`&"P62\<0+;\1M*P4A(E``U1`$
M0>`#>G1"C.`>)@`$:\F>EH`FV8A*B<!)3S-_A5`!3-``,O`$/8`#.0"D&9`&
M(T"/#Q``3T`'2R`'&1``!C`#8[`"1+"$5%#_*':@!PA`!C2)`-I8`@`0?D`!
M!`_@K2E@`@RP`"-`!$M!.SP0!D\0!BJP'@M`!A@0`A*``R3``AE04NS8`W6@
M!F2``.HF'W\``\#@!O^A'V\``2!@`B.``!=`!F/0`!F@``L``SU6(FP5J!@*
MKS`P`.B)!21@`4T0:0/``19``4H@@C_@'B743-2B+GJ5##)P!$?@`U)PHY90
MMBKB-(733%L229$$.,=U`3VP!$&P!#_`/PY@-"H@`1G0`SXT`P+P`[+#NT%0
M/4+@!54`!1]0!`)@E&*E!`^P`,M2"!@@!IF*`[>;`0[0`%<``'#P6W]P!AU*
M`J<@`@\Z`_V[!6J0_P8/@(E?@`<;1@8!00,L,``S=B%;\+T"80&K5IUK(`(J
MD`4W(#,78#H#X`8*\`8'X$%`,&5.\`4+\`8Y()2ZYP`[``84<%*F-#R29"IC
MXB^4H[OX^R;9:0EJES9PC"VCV@C25#:2!$=J9P+0EP$+0!`4T```H"T%4`(U
M0"E_L`(LX*2C4G4W,``]T"P9$`(?H`-0(`$!\&)X\`4E,`8/(&0F@*4-<`=F
MT``[,&,28`8&@``4L`\B@``_@`!?100"(`(.P`)_%0`JP`;`R0M^002#T*4Z
M8&Q(H`!P<`$[0`+\TP,D@`.U)0.I4@`7@#0B,,8'8'T&(`$0P"`_$`)?0/^N
M'``)`N`:U%D%/."AJ"2JW.,(K!H*;FL([:P(H"PJ"/,UB=!,YX0&)Y*^?^"R
M"$`V86,!!L`'"O`![T8!4`L`#T$&(^"G4Q`#8RP(&_``%V``:6`%3M`'%<`&
M'4`%YR,[%;`#,&`!4+`J'1`"5%``(U`!$J`"D)<$.S`&1<`+56"\<"``P&P!
M/*`&8,`#)``#"]"4?]`$*C`#Y*P`,M`&%-`#)4`#?#`"3J!G?V#(2J`!^&,&
M*$`"-:T`#&`!<_8'([`!%^`&+J`!G8L".BH$$``!`MG&690\)G!*97*$_^(M
M\GNV5;,(9G(X>XDWBC`]HHK'B<`8NP!"A[`'"+#_`&P8`Q;0`SHP!0AP!#BP
M`;Y%!B#`!KY%`4&```/``$N`?1L@D%Q``S6@`P_`!0Q!HNDG"'H@?0NP`%R(
M`4M0`U.P`Q60KV0E"%F``APW`#0`T2&@5AM<`#&P`2$P!0T`!:PRU"[``9FR
M`BA@(FS``E-@`1NW`F/@)@]@`7^`!#N@!C(0!CW0`'`0`CB`-(*0O79``0@@
M#P,@9_5!`W=`!"M20N=K2=8R->Z9`.X!!.ND"M<")T]3QAYC/.R2+];B`7&`
M!UE$)JRJWPE$?\:'!Q_SER>R*7:PI]?T!6U0`6]Y`T+0!`RR!1\@`A4@!1\`
M`C?P`6+)`$UC`CFP!FM@_R(QX`YM($<5$`0B((@5(.,R8`)F[3.\8`?&92D:
M<`0F@`%'(!\:(`-8@`$:``;53`&,X052)0CM*PA>8.(7`(/@HBLRP$U>@`0,
M$@-($.8R<`-Z8$@R4`%8\`%OJ04:H`<^8`9(%DT'R$4$8UH,*37P%`%*4$E2
MD^`8]3$8%==3,^B6!`19ITK'(XPNTPA:@`:R85JQP<^\@`8*,RU*0"UWK03'
M!Q!:LB)`4-B.8`!N,!D+`,S$4+8YL`<U$`86-&YIPUBGI-]9A(ZJA#=X8#RD
M1%7J<NB^KNA?8S'K=,<$6#DSI#V#;@+R<B)O7%UJ^\Z";7:6L)ZKH#9W[`@@
M<)<`:L`SP^#7$2Y3!\`!=V@I>*#/B,`NE7(MGA['C4``)J!MA!`!DZ4]V#;7
M!',QD>0O@G#OA`-'(60(<4P`]FXIT6XV@I!UC*`E#*\*8%OM,N(MH7X,QW?7
M&<8+>;!MVV8"C(4P:1L]9%3'F'`W>9`'X64(ZY3LEV!)A]`];FQ:\NY,!^]=
4^W.UUF[SL.`E_.Q,`/'PEQ`(`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g14343g1434301.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g14343g1434301.gif
M1TE&.#EA&P$<`.8``&MF9.3EX]34T?GZ^K*QK%Q75<S,R=O<V??Z^KJZM<+"
MO<3$P/7V];V\N?G\_?'R\:ZLI?[^_IV:E6%<6P8$!7EU<ZFGH;6TL,G*QOS^
M_H&`@*JHH>WN[-G9UCLV-BHF)G!K:M+2SJVKJ::DG8%]>I&/B_S\_+"OJI62
MC5),3)63DO+U]4Q)286!?M78TZ*@F79R<1H6%^[R\*">EYF6DNOLZN'AWZ:D
MHM#/S(V*B;BVLWYZ>(R)A8B%@NGJZ-WAW4E%0ZJHI9V:F>7IYL?&Q,[0S$`Z
M.T="0?3T\G5P;>CIYO;W]JRKI,"^NWQX=?#P[\?(PNWP[J.AFJ6CG?'T\NSL
MZMC7U4Q(1J*AG>GM[&5A7[BXLOK[^]_>W#`K+*>FG[[`N:NJHM;9UT0_/^SK
MZE514"`<'.?LZ30P+S4N,>_O[F)?7@T+"Q,0$?S]_?CX^$]'2,G'QZ:JI:.?
MH,[0T*.DG^#DX/O[^YV@H"(@'^?GY24B(L'`P/W^_@$``/___R'Y!```````
M+``````;`1P```?_@'^"@X2%AH>(B8J+C(V.CY"1BA9E*04%*5<J58@E!6N8
M+&4'7`M7906H0A&2K8<1%A.7*4<E-8-]60$_`799KL#!PL/$Q<0M;7[*RGL7
MKWG+RFQ%'`71?BQNQI%]$]=`(8,R"@0O$!M;V^KK[.WN@T1HUVPJK(48,==F
M?TMKURSO&/F+QD+`("H-F-`(\R),P(<0(TK\P\7;M1U+#&EA$XU"@3\,K!&<
M:&C@LBL&!;E1<$+"%@L02,J<23/2#H[1RG0PM(="-#9!_KPAD<>,T3T@["U2
M:JC/HS[:!IE4AG*0`P,*MF!54+.KUZ]_&GC1=Z/0`YS+S(2+8,/"E!$6_TYT
M8)J(+J&H2]VX<4!HJA]P=Q$X&-`'`=C#B"$^$+F,0HY"-'Q&<\+A3X0#(D1<
M$''"BJ`0FB^<".*YD(`3FRT$.8!7$!$:(-9,6*,%P`X"45H+\@O8JF#!#!`A
MB!*@BPL!76J82,R\.:,>^:(!"#YHS#4_<98/(/%A3_</,/[<R?&A?/DU<0H!
M^."E^YX>2`;AT.+!C&1E%-A\F""BY+=P@W2P`!0*%)$2(0CX4`08!!"PP08$
M)`"%"SZ\X=R%&"H`Q#4>V$!(=,NT$8`@(?WSAPD:W.='&RH04H4\T920T1\B
ME''=-11X<(.%4EUS!`Z$+/#6#"<D0$@$5+C0P/\&4IC#!`00C-`0&#\LA^&5
MB#T`PS5M&#!(`&@IDT)\(&EAXA]!?'"-!H008,9/&+`2P5@WXH@&@+OY"*0@
M?2Q@`1-2G)#.(%RX$,8,+T@Q!0$6?`&!HTR,``8'=F%IJ4PJ@*B,"#,FH2(%
M<=C3SYEJ;!G-%>GMIN(12H"4`XY&R(&'$2K2TY>>5B4PPQ>!#FH9!Q=(8`X$
M#=@1@!Y=)"#!"%]L4,2,ET8K$Q%77%.!'H+0&2*V@BQAT3(`"9*#BF8(H1(+
MUT@PP!]Z>-`1"Q@L\<`"(*QY:S0_6K7`DR\P0<`@;MBP@01,G`"!"R:P,L`!
MS5HP@P(/2%N,7I95VA7_7Y(P4,$U7NP9IA])0%OB2((T841'/0BR@+9^L.'E
M'VH44%Y['I1F60/V]HCOGG\XL``$87Q1,,`=3"'%!4`;0(4@$2"@A!X!!,#!
M'<%8_([5$3A52`1,]>$UUW=IO=21Q&0@B-F19)!!"6&RP<<?!JCHQP%*C0RN
M.*8NHX4:?Y"0S#(>W'*B``LL0(3A@SQ`@'71L*GS,OD*XH`"3%BP`92#1!``
M0QN$L0$3&-@A`\9@?\6%;JU838S8D93^D`YO1G,!%SMP68C=RH0K"-O1?/"V
MC='P8(\;60N2``AC?!!#&VS([7B>.UM%N>68#\(`&%/T2X`4S9X`1A%%_&`8
M_R$!$-#`%EN`,>(PK!]I\0I<_.$&`^WWC(@)T#920_Y@]2$#(\7+W!L8MXP"
M'"`%U]#"[1B3.T*8K".V(."*^C,$K0WA",V3VW6>]P>_1*YGT[M<3`#V@P9(
MB0E;<-`(IC"%&8P@`2%80;>"4`84T"`'/,#`UQBQ`J9$("KU8X0.P/``##"!
M;XMX0@D>H8,%"*(%3<"8,`8@PT)X37*H(T02!'$`$+S",EK+@`.8,@$5Q8`(
M1[A&90B!.VP0X@T:L%8)8J>,">RD,%RX0//JM,%[08YGDZN<"`OAAB@4X01!
M^X+EP@`!I$G@"P;(B!M.```?D.%IU(G`&ZC6!P8\8/\`PP/)$]:%A%)6J@^E
M1(+8!E!*JOV!!EA0`@%*X(,_].$!#T""4@QS&3AD\@T/8("5",&%'@CA#1&`
M01/>@`1D#L($2/@D+B(P(U8B(9-ND%<SWUC*A*G$'D[IPQN,$)PEB&$02[AF
M_$`Y``ZHH8=*<<`%]M`1+4!C&6PP1!MU)P@AA.D*M(H&`=9EF0[`J",Q`(`0
M5)`SZ/U1>H*L'B'$^00E8``*8+B`!5X`*2D08$1<.$%X",$!%RR`!@<PP0)V
M```:""`C,,S!&E2@!A*`H`6M$L3X[F"`'52@`BFAPA1`4`$=Q(<&7_#!"5!`
MACXH````2$(77.D4#H`@!CW_>(`)`E`"`)#@`CP:A`Z.P`()<*`"-Y``#%#P
M4GXP`00`F$%\(M"$(O2@"UP(0A*<L`,?:$X!(@!!$EZ`1#74@:@)B)@-7$"=
M!"!!`!+`Z@!DX()?Y>"F6"!,#2P`U1L(CFE(D*`?8J"B,NB3@6XDA`'4M(P8
MA*D-1"`$,CHR`3X80`\KX$-#.X@KR850HK9$F_R6P``DE'0+4H#0@US`!01<
MH`6%"`(0RM"`/X0!`$WX@P0*8)`RP.$`#UB#%PRR!1`X18H&,((#,D``$HR(
M!COX0P:2\)@OG*`&$*!!%0X``"7T(0-&X)D@;&`$00A@`C$)P0XD0)U!M,!<
M?RC`_Q&J.P,`>*8"`"##&WH``$&8(07_2\`:*)*`(_R!#QZ`L`J<(`@2E*`/
M>IA`66`@@*@`H`'+\<!G/J(&+U2V"B4@P1+J,&($J&"DA)C`QZ[!A_;MTQ#`
MJY,6ND"(,9B1$$A`P6X]",C?CE!^=H""`2YZ@(E&H0$M'`$$Q."`!_`@#V/P
M@!$`@(,@`$`'@@"!D9YH`348H99_L$*!_R"`%!3"!A6`PB`:T``=Y.`,@NA`
M"8K&!!^,0`I/",(._O>'I![:Q!DPP`06C>1!\&`.@BC`OP0!A#@X(`41^\,3
MTB`(-(PH`E3ZC&EU4``["((**&B"$+"PM#]`@0<'(($8HO^B!07$SPN?24H"
MMB@(-4C`!`VH@"`,X(Q")(!EUXC!R]X(@&L8NA`M6/(RWD:(@*;E;(2F9^/\
M*":;3>Z1C5KU'P9@``E(@``%$QL7RJ?(#8R@S&&);YMZ\#(05%<09VB!%8#P
M!$$$``@&AH-I3%L((:0!#BE(@1$\@`-_!Z`!+<"6$[R0`@G$FA!=T+$-2H#G
M`=-@W.)"]1]`D%U!E,$`68B!$>!0@#'DTP%:B/4`MAOG`C<`R1&0@`Z<,(8)
MP.$('O``$1+-(Q)@0!L:_X,/6H"$,JQ/M2GP``!B2XCU_@%=4CZ[];[5P$*$
MP%TWBD&J!I&"3U7`*45(XY9[*PC_*/2K45_N0P`@(`&80``#D!:*&'@%)0AX
MJ`\Z",\5_T``"2!<F8/8`@T"`&M!#"'L.!A#(:R@!?_:4@\^F$,/>/2&`#!`
M`EC0@P[,>H`H_*$(,[@"SME28"1<0-L&+H'<_Z`!",.`W7]`50><0)T[I&H"
M?$/"!`C0APC08<076`./N$""&ZA@#@1%@@T8X`0,\*@`([`0K0FMA3=4X.'\
M$``5`O``A*P!!A;B`%)4`7^#(PU0/TM@)B2C'AKD!SU`!H5P`IK2&'6R`\/$
M&SSC!D+R*!!"3`(P,"_P%E'R`E)R:1YE`+&6`-I&,7\0+`B7!#<0,610`'S`
M!2E0<7]P_P!A%P(81SY.0`-Z$0`J<`$H!R`X0`,V0`-2H`1-HD0B8"%]L`8]
MQS0'D`86@@-K,"(,0``[,#ZF1@,9X7"#8`1$X`9CT`$F,``=H&-_4`'Q\0!P
ML!=O0``?8`(7P`*ED6Q\0``HX!D#X&A)R`,C4@5FL`7:,'\'$!X8``+QL01\
M``(=,`,$H`TGL`.?-0@&<%#1T`88<`A/9@B9<AT4X$2%X`-`T(!^0`$%J`P`
MP"V\%0UC,&X,D``O8`%2$`;=QC0RL``,,0-3`#27PTA?\`50$`6LT`=$@`*%
M``4GX"%_@`$DL!I=M1-)0!T!0&T'0&V$T$4'(``\0`,1<P,DT/\!5N`$YA($
M]Z4K'&`%V&4%8E`&-L,*2K`&1-`'-M`"XSAU%N`ZG%<"..`&.3!N:X`#?=`#
M/8`#"]`#7R`(,!`QVE<$![```%`&2L`'8Z`"77``);!$;E8"5D`$:W`"?\`!
M=]8!$F`$7_<'8V`%;F``CY$%*7`!5M``$V`0?```(7``.8!\MU,&;/"30,D&
M!>",A;`$(!"40GD(10`$2*D?-K.-1K!'C=$&'H`%9A"48Y"+1QF4*8`G*P`%
M6Y``!*``7%$(,M`%"W`!C/0"+A0&6[``+L!I@J`'./<'-3`$!/4'*]`#($`#
M:[0`6M,'`/($8'`('0`"(!`$4;$$E'3_8X+@`UG07#^P+BL``VNP`S\0/X*P
M+GU@!R-`2A```"W`=H4P`(PV`+8G'VI@&`0``C"@;TU@)57@FCG0`0)@`PM0
M`2)0`4D0!)K)>5YU`%K3!2V@9VAH>M.Q5::V!DY`94)A`+Q)`/R(B<7I!!4`
M`S#@!!#X"D6`F#!0`22P9X9P`4Y@G3X%`CHP3``3`0[0`QY0%&;P`1X0%%5`
M`]9YG3F`)SI0`7`%5P308'JY`C)P!BOP"X>P`D-@FTVP!04R!%XH#$%D&8@`
M%>K`"AD10%LC-FH#":H3%J4F'$SQH*W`@LR!`%DD,>MPHA+A!L)E"!V*"%;0
+'X?1?2A:$X$``#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
